表柔比星联合多西他赛或紫杉醇治疗乳腺癌的效果分析  

Effect of epirubicin combined with docetaxel or paclitaxel in the treatment of breast cancer

作　　者：武政喜[1] 鞠敏育 张志业[1] 李建峰[1] 许学明[1] 

机构地区：[1]宁夏石嘴山市第一人民医院普外肿瘤科,宁夏石嘴山753200 [2]宁夏石嘴山市第一人民医院检验科,宁夏石嘴山753200

出　　处：《中国生化药物杂志》2017年第7期251-252,254,共3页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的比较表柔比星联合紫杉醇、表柔比星联合多西他赛治疗乳腺癌的疗效及预后。方法研究组采用表柔比星和紫杉醇治疗,对照组采用表柔比星联合多西他赛治疗。结果 2组乳腺癌患者治疗结束后进行为期5年的随访,研究组5年生存率（86.67%）高于对照组（68.89%）,研究组复发率（4.44%）低于对照组（15.56%）,差异有统计学意义（P〈0.05）。结论表柔比星联合紫杉醇治疗乳腺癌效果优于表柔比星联合紫杉醇。Objective To compare the efficacy and prognosis of epirubicin combined with paclitaxel and epirubicin combined with docetaxel in the treatment of breast cancer. Methods Patients in the study group were treated with epirubicin and paclitaxel,while the control group was treated with epirubicin plus docetaxel. Results The two groups of breast cancer patients by the end of the treatment were valid for 5 years of follow-up,five year survival rate（ 86. 67%） than the control group（ 68. 89%）,the study group the recurrence rate（ 4. 44%） than in the control group（ 15. 56%）,the data had significant differences（ P〈 0. 05）. Conclusion The epirubicin is conducive to breast cancer patients for better disease control effect and prognosis than star,paclitaxel combined with chemotherapy.

关 键 词：表柔比星 多西他赛 紫杉醇 乳腺癌 疗效 预后 

分 类 号：R737.9[医药卫生—肿瘤]